-
Expenditures on oncology drugs and cancer mortality-to-incidence ratio in Central and Eastern Europe [Elektronski vir]Vrdoljak, Eduard ...Background. There is a steady decline in cancer mortality in Western Europe (WE), but this trend is not so obvious in Central and Eastern Europe (CEE). One of the largest discrepancies between WE and ... CEE is the level of investment in cancer care. The objective of our analysis was to examine the correlation between mortality-to-incidence (M/I) ratio and expenditures on oncology drugs in CEE and WE. Materials and Methods. This cross-sectional analysis was done on publicly available data. Data on expenditures for oncology drugs were obtained from QuintilesIMS, and data on M/I ratio from Globocan. The main outcome was mortality-to-incidence ratio, and the primary analysis was performed by Spearman's rank correlation. Results. There is a large discrepancy in expenditure on oncology drugs per cancer case between WE and CEE, and within CEE. Average expenditure on oncology drugs per capita as well as per new cancer case was 2.5 times higher in WE than in CEE. Availability of oncology drugs was highest in Germany (100%), relatively similar in WE (average of 91%), but in CEE it ranged from 37% to 86%, with an average of 70%. Annual expenditures on all oncology drugs per new cancer case was significantly negatively correlated with the M/I ratio (Spearman's p = -0.90, p < .001). Conclusion. There is a financial threshold for oncology drugs per cancer case needed to increase survival. Based on significantly lower expenditures for oncology drugs in CEE in comparison with WE, more investment for drugs as well as better, more organized,value-oriented consumption is needed. Implications for Practice. Cancer is not treated equally successfully in Western Europe (WE) and in Central and Eastern Europe (CEE). This study showed that success in treatment of cancer is associated with the amount of money invested in oncology drugs. CEE countries spend on average 2.5 times less than WE countries for oncology drugs per new cancer case. These findings should be used by healthcare providers and oncologists struggling for more resources and better, more organized, evidence-based allocation of these resources as well as better oncology outcomes.Vir: The oncologist [Elektronski vir]. - ISSN 1549-490X (Vol. 24, no. 1, Jan. 2019, e30-e37)Vrsta gradiva - e-članek ; neleposlovje za odrasleLeto - 2019Jezik - angleškiCOBISS.SI-ID - 2048440689
Avtor
Vrdoljak, Eduard |
Bodoky, Gyorgy |
Jassem, Jacek |
Popescu, Razvan A. |
Pirker, Robert |
Čufer, Tanja, 1955- |
Bešlija, Semir |
Eniu, Alexsandru |
Todorović, Vladimir, medicina |
Kopečková, Katerina
Teme
Neoplasms |
Mortality |
Epidemiology |
Incidence |
Pharmaceutical preparations |
Economics |
Novotvorbe |
umrljivost |
epidemiologija |
Incidenca |
Farmacevtski preparati |
ekonomika |
Europe |
Evropa |
cancer |
oncology |
Central Europe |
Eastern Europe |
drug expenditures |
rak |
onkologija |
Srednja Evropa |
Vzhodna Evropa |
izdatki za zdravila
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|---|
Vrdoljak, Eduard | |
Bodoky, Gyorgy | |
Jassem, Jacek | |
Popescu, Razvan A. | |
Pirker, Robert | |
Čufer, Tanja, 1955- | 12179 |
Bešlija, Semir | |
Eniu, Alexsandru | |
Todorović, Vladimir, medicina | |
Kopečková, Katerina |
Izberite prevzemno mesto:
Prevzem gradiva po pošti
Obvestilo
Gesla v Splošnem geslovniku COBISS
Izbira mesta prevzema
Mesto prevzema | Status gradiva | Rezervacija |
---|
Prosimo, počakajte trenutek.